Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Closing of $149.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Research Alliance Corp. II (Nasdaq:RACB) has successfully completed its initial public offering, closing on March 22, 2021. The offering consisted of 14,950,000 shares of Class A common stock, including an over-allotment of 1,950,000 shares, priced at $10.00 per share. This resulted in gross proceeds of $149,500,000. Sponsored by RA Capital Management, the company aims to utilize these proceeds for business combinations within the healthcare sector. RACB shares began trading on Nasdaq on March 18, 2021.
- Raised $149.5 million in gross proceeds from the IPO.
- Proceeds intended for strategic business combinations in the healthcare industry.
- None.
Research Alliance Corp. II (Nasdaq:RACB) (the “Company”) announced today that on March 22, 2021 it closed its initial public offering of 14,950,000 shares of Class A common stock, including 1,950,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at
The Company, sponsored by RA Capital Management, L.P., is led by Chairman and CEO Peter Kolchinsky PhD, CIO Matthew Hammond, PhD and CFO Tess Cameron. The Company is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry. The proceeds of the offering will be used to fund such business combination.
The Company’s shares of Class A common stock began trading on The Nasdaq Capital Market under the ticker symbol “RACB” on March 18, 2021.
Jefferies LLC served as sole book runner for the offering.
The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: 877-821-7388 or by email: Prospectus_Department@Jefferies.com.
Registration statements relating to these securities became effective on March 17, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005722/en/
FAQ
What was the purpose of Research Alliance Corp II's IPO?
When did Research Alliance Corp II go public?
How many shares were offered in the IPO of RACB?
What was the offering price for RACB's shares?
Who was the underwriter for Research Alliance Corp II's IPO?
